2021
Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN)
Roth JA, Trivedi MS, Gray SW, Patrick DL, Delaney DM, Watabayashi K, Litwin P, Shah P, Crew KD, Yee M, Redman MW, Unger JM, Papadimitrakopoulou V, Johnson J, Kelly K, Gandara D, Herbst RS, Hershman DL, Ramsey SD. Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncology Practice 2021, 17: e1821-e1829. PMID: 33797955, PMCID: PMC9810137, DOI: 10.1200/op.20.00770.Peer-Reviewed Original ResearchConceptsMaster protocolsPatient knowledgeCell lung cancerOncology clinical trialsMost participantsMaster protocol trialsMedian ageEligible participantsLung cancerLung-MAPClinical trialsOdds ratioGenomic resultsCancer riskProtocol trialSociodemographic factorsCancer treatmentPilot studyCancer diagnosisTelephone surveyRiskCorrect responsesDemographic factorsCancerDescriptive statistics
2002
Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial.
Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Daniel Ayers G, Herbst RS, Abbruzzese JL. Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. Journal Of Clinical Oncology 2002, 20: 3785-91. PMID: 12228198, DOI: 10.1200/jco.2002.04.084.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAttitude to HealthClinical Trials, Phase I as TopicCollagenData CollectionDecision MakingEndostatinsFemaleHumansInformed ConsentMaleMass MediaMiddle AgedMotivationNeoplasmsPatient ParticipationPeptide FragmentsPhysiciansProspective StudiesResearch DesignSurveys and QuestionnairesConceptsPercent of respondentsPhase I clinical trialPhase I trialHuman recombinant endostatinI trialClinical trialsTrial investigatorsResearch participants' understandingTrialsEndostatinPhysiciansRecombinant endostatinPotential influencePercentProspective participantsTrial purposesSurvey respondentsPersonal benefitsParticipants' understandingPatientsRespondents